PDA Technical Report No. 27 (TR 27), titled "Pharmaceutical Package Integrity," is a foundational guidance document for evaluating the barrier qualities and seal integrity of pharmaceutical packaging, with a primary focus on sterile products.
Originally published in 1998, it establishes a framework for Container Closure Integrity (CCI) testing throughout a product's lifecycle—from initial design and process development to routine manufacturing and long-term stability testing. Key Content & Coverage
The report provides detailed guidance on maintaining an effective microbial and physical barrier against contaminants and reactive gases. Its structure typically includes:
Integrity Assurance: Strategies for assessing package integrity during development, in-process controls, and final product testing.
Leak Rate Specifications: Establishing desirable leakage limits based on specific product and package performance.
Test Method Selection: A review of various leak detection methodologies, including a Decision Tree to help users select appropriate methods for their specific needs.
Microbial Integrity: Guidance on establishing microbial barrier effectiveness, which is critical for maintaining sterility. Current Status and Availability Technical Report No. 27: Pharmaceutical Package Integrity
I cannot directly provide or link to a PDF copy of PDA Technical Report No. 27 (TR 27) Pharmaceutical Package Integrity due to copyright restrictions. PDA reports are proprietary documents protected by intellectual property law. pda technical report 27 pdf
However, I can give you a representative excerpt based on the known content of TR 27 (2006, currently reissued as TR 86 for container closure integrity). This is a synthesized piece that reflects the style and technical focus of the original:
Excerpt (Illustrative of TR 27 content):
4.3 Deterministic vs. Probabilistic Leak Test Methods
Historically, package integrity testing relied heavily on probabilistic methods such as dye ingress or microbial immersion challenges. While these methods provide valuable pass/fail data under specific conditions, they are subject to sample size limitations and do not guarantee detection of all critical leaks. Probabilistic methods require the simultaneous occurrence of multiple conditions (e.g., presence of liquid, pressure differential, organism size, growth conditions) to yield a positive result.
Deterministic methods—such as vacuum decay, high-voltage leak detection (HVLD), or laser-based headspace analysis—offer distinct advantages. These methods directly measure a physical parameter correlated with leak size (e.g., pressure change, electrical conductance, or oxygen ingress). When properly validated, deterministic methods provide quantitative, reproducible results with known sensitivity limits.
A key concept introduced in this report is the Maximum Allowable Leakage Limit (MALL). The MALL is the largest leak that still maintains product sterility and stability throughout shelf life. It is not a universal size (e.g., "10 µm") but must be determined empirically for each product based on microbial challenge studies, viscosity, container closure design, and worst-case orientation. For many sterile products, a leak corresponding to a 5–10 µm diameter capillary may be acceptable, but lyophilized products may require tighter limits due to oxygen sensitivity.
If you need an actual copy, you must purchase it directly from PDA (Parenteral Drug Association) at www.pda.org/bookstore. For open-access guidance, refer to USP <1207> (Container Closure Integrity Testing), which is publicly available in draft/summary forms. PDA Technical Report No
PDA Technical Report No. 27, "Pharmaceutical Package Integrity," provides comprehensive guidance on Container Closure Integrity Testing (CCIT) to ensure the barrier quality of pharmaceutical packaging, particularly for sterile products. It outlines strategies for establishing integrity standards and selecting appropriate test methods, such as helium mass spectrometry and microbial challenge, throughout the product lifecycle. The full report is available for purchase at the PDA Bookstore. Technical Report No. 27: Pharmaceutical Package Integrity
The air in the sterile processing lab was thick with the hum of the autoclave and the scent of pressurized steam. Elias, a veteran validation engineer, held a worn, printed copy of PDA Technical Report No. 27 (TR 27) —the industry bible for Pharmaceutical Package Integrity Testing
To the uninitiated, it was a 1998 document full of leak rates and gas chromatography; to Elias, it was the only thing standing between a perfect batch and a multi-million dollar recall. The Midnight Breach
It was 2:00 AM when the alarm on Line 4 shrieked. A tray of glass vials, intended for a critical life-saving vaccine, had failed the preliminary vacuum decay test. The junior tech, Sarah, looked panicked. "The seals look fine, Elias. Maybe the machine is just out of calibration?" Elias didn't guess. He flipped to the section in Physical Test Methods
. He knew that while visual inspection was a start, the report emphasized that "quantitative, non-destructive methods" were the gold standard for detecting the microscopic paths where bacteria could hide. The Search for the Micro-Leak He walked Sarah through the logic laid out in the report: Identify the Barrier
: They weren't just looking at glass; they were looking at the "container closure system." The Torture Test : Using the principles of Helium Leak Detection mentioned in the PDA guidelines, they traced the seal. The Discovery
: Under the intense scrutiny of the leak detector, a tiny spike appeared. It wasn't the glass at all—it was a microscopic defect in the aluminum crimp of the stopper, a flaw so small it was invisible to the human eye but large enough to allow microbial ingress over time. Validation of the Cure Excerpt (Illustrative of TR 27 content):
"TR 27 says we don't just fix the one vial," Elias explained, pointing to the section on Maintenance of Sterility . "We find the root cause in the capping pressure."
By dawn, the machine was recalibrated, the faulty crimper replaced, and the integrity of the batch was verified. As the sun rose over the facility, Sarah looked at the technical report with newfound respect. It wasn't just a PDF of regulations; it was a roadmap for safety.
Elias tucked the report back into his desk. "In this business," he said, "we don't believe in luck. We believe in the PDA." specific testing methods outlined in TR 27, or are you looking for a summary of the 2026 updates to sterile packaging standards?
TR 27 defines integrity not as a binary "pass/fail" based on visual inspection, but as the ability of a container to prevent the loss of sterility or product quality. It introduces the concept that integrity is a probability, not an absolute.
Even if you transition to TR 84, the legacy of TR 27 remains in three key workflows:
Pro Tip: When you purchase the official PDF, you receive a watermarked copy with your organization’s name, which is acceptable during FDA audits.
TR 27’s Recommendation: Use deterministic methods whenever feasible; microbial challenge should be used only for validation of deterministic method sensitivity limits.
TR 27 introduced a risk-based concept: not every leak must be detectable. The MALL is the largest leak that still ensures sterility over the product’s shelf life. The report guides you to set a MALL based on:
For those unable to immediately obtain the PDF, understanding these core principles from TR 27 will improve your packaging program even while you locate the full document.